Bangalore, Feb 25, 2010: To protect against the increasing threat of counterfeiting, India-headquartered Bilcare Technologies has launched a patient safety system, nonClonable, in the US market. According to the company, taking a holistic approach to ensure the authenticity of medicines and help patients comply with medical prescriptions, the nonClonable system secures the supply chain and provides validation to various stakeholders including the patient.

Bilcare Technologies unveiled nonClonable at the Fifth Global Forum on Pharmaceutical Anti-counterfeiting taking place in Miami, Florida, US. The subject of the conference 'End-to-End Protection -- from API to Patient' emphasizes a key problem faced by the worldwide pharmaceutical industry that has grown in complexity and extent over the last decade. Bilcare's nonClonable is said to provide a comprehensive solution to help address these issues.

"Counterfeit drug sales will reach $75 billion globally in 2010, an increase of more than 90 percent from 2005 as indicated by the US-based Center for Medicines in the Public Interest and the World Health Organization. Bilcare's unique nonClonable fingerprint technology can be easily incorporated into packaged medical products at both the primary and secondary level so as to make the medicines extremely secure," said Dr Satya Sharma, Chief Mentor, Bilcare Technologies and Executive Director of the Center of Excellence in Wireless and Information Technology (CEWIT).

He further said, “The technology exploits the intrinsic nature of micro and nano-structured composites to give items complex and unique 'fingerprints' on an item level. By making use of proprietary readers and a brand authentication system, not only is patent safety enhanced, but real-time data delivery can save stakeholders time and money."

The company says that the design of the system is flexible enough to comply with future legislation such as pharmaceutical e-pedigree requirements, which are expected to be enforced in the coming years in US. Therefore, brands can invest in this new technology today in order to reap benefits at the earliest, while knowing they will be in a position to meet future legislative requirements with only modest upgrades and fine tuning.